GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » Cyclically Adjusted Price-to-FCF

DiaMedica Therapeutics (DiaMedica Therapeutics) Cyclically Adjusted Price-to-FCF : (As of May. 23, 2024)


View and export this data going back to 2007. Start your Free Trial

What is DiaMedica Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


DiaMedica Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for DiaMedica Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DiaMedica Therapeutics Cyclically Adjusted Price-to-FCF Chart

DiaMedica Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DiaMedica Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DiaMedica Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, DiaMedica Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DiaMedica Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



DiaMedica Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

DiaMedica Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, DiaMedica Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.176/131.7762*131.7762
=-0.176

Current CPI (Mar. 2024) = 131.7762.

DiaMedica Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.013 100.560 -0.017
201409 -0.775 100.428 -1.017
201412 -0.040 99.070 -0.053
201503 -0.108 99.621 -0.143
201506 -0.144 100.684 -0.188
201509 -0.053 100.392 -0.070
201512 -0.119 99.792 -0.157
201603 -0.093 100.470 -0.122
201606 -0.090 101.688 -0.117
201609 -0.194 101.861 -0.251
201612 -0.229 101.863 -0.296
201703 -0.149 102.862 -0.191
201706 -0.239 103.349 -0.305
201709 -0.112 104.136 -0.142
201712 -0.157 104.011 -0.199
201803 -0.148 105.290 -0.185
201806 -0.132 106.317 -0.164
201809 -0.237 106.507 -0.293
201812 -0.216 105.998 -0.269
201903 -0.262 107.251 -0.322
201906 -0.240 108.070 -0.293
201909 -0.103 108.329 -0.125
201912 -0.155 108.420 -0.188
202003 -0.227 108.902 -0.275
202006 -0.060 108.767 -0.073
202009 -0.141 109.815 -0.169
202012 -0.161 109.897 -0.193
202103 -0.230 111.754 -0.271
202106 -0.111 114.631 -0.128
202109 -0.160 115.734 -0.182
202112 -0.106 117.630 -0.119
202203 -0.147 121.301 -0.160
202206 -0.094 125.017 -0.099
202209 -0.089 125.227 -0.094
202212 -0.105 125.222 -0.110
202303 -0.193 127.348 -0.200
202306 -0.184 128.729 -0.188
202309 -0.127 129.860 -0.129
202312 -0.100 129.419 -0.102
202403 -0.176 131.776 -0.176

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


DiaMedica Therapeutics  (NAS:DMAC) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


DiaMedica Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


DiaMedica Therapeutics (DiaMedica Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Executives
Jan Stahlberg 10 percent owner C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Scott Kellen officer: CFO and Secretary 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill 10 percent owner SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls director, officer: President and CEO 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto 10 percent owner 394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke officer: Chief Business Officer 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt 10 percent owner C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Koch Thomas Von 10 percent owner TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Ab Tomenterprise 10 percent owner C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba director TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves officer: SVP Clinical Development Oper. 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305

DiaMedica Therapeutics (DiaMedica Therapeutics) Headlines

From GuruFocus